Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INS19 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Immunochina Pharmaceuticals
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
INS19 CAR-T cells are an investigational chimeric antigen receptor T cell (CAR-T) therapy developed by Beijing Imunopharm Technology. This therapy involves engineering a patient's own T lymphocytes to express a synthetic receptor targeting CD19, a protein commonly found on the surface of B lymphocytes. The modified T cells are designed to recognize and eliminate CD19-expressing malignant or autoreactive B cells. The primary indications under investigation include relapsed or refractory acute B lymphoblastic leukemia, B-cell leukemia, pre-B-cell acute lymphoblastic leukemia, and systemic lupus erythematosus. As of March 2025, the drug is in Phase 1 clinical trials[1][2]. The mechanism of action centers on CD19 modulation and replacement of dysfunctional T lymphocytes.
- Other names
- INS19 CAR-T CellsINS-19 CAR-T CellsINS 19 CAR-T Cells
02
Targets
Beyond the preview
Go deeper on INS19 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INS19 CAR-T cells.